Organizing Committee

Cindy Toze (Vancouver) Mike Voralia (Saskatoon) Spencer Gibson (Winnipeg) Chaim Shustik (Montreal) Loree Larratt (Edmonton) James Johnston (Winnipeg) Christine Chen (Toronto) Steve Couban (Halifax)

AGENDA

Thursday, September 30, 2010

7:30 - 8:00 am	Breakfast
8:00 - 8:15 am	Welcoming Address James Johnston
8:15 - 9:15 am	Keynote Address Clinical research in CLL: A vital mission Clive Zent, MD Mayo Clinic Rochester, MN

Session I — Stem Cell Marrow Transplantation in CLL Chair: Dr Cindy Toze

9:15 - 9:45	Harnessing allogenicity as a tool in the treatment of CLL Donna Wall
9:45 - 10:15	Allogeneic stem cell transplantation for CLL in 2010: Fine tuning - what can we accomplish and what can we not? Cindy Toze
10:15 - 10:45	Coffee
10:45 - 11:05	NCIC clinical trials in CLL Stephen Couban
11:05 - 11:25	Lenalidomide and AKT inhibitors as novel therapies in CLL Christine Chen

11:25 - 11:45 am	Valproic as an HDAC inhibitor in CLL Ju-Yoon Yoon					
11:45 - 12:00 pm	Elizabeth Locatelli-Turgeon					
12:00 - 1:00 pm	Lunch					
	Session II — Clinical Studies Chair: Loree Larratt					
1:00 - 2:00 pm	Keynote Address Familial CLL Susan Slager, PhD Mayo Clinic, Rochester, MN					
2:00 - 2:20 pm	lgH abnormalities in CLL Tanya Gillan					
2:20 - 2:40 pm	Retrospective CGH/SNP microarray analysis of CLL patients over a period of 14 years Shashi Shetty					
2:40 - 3:10 pm	Coffee					
3:10 - 3:30 pm	Clinical MBL and CLL: A continuous spectrum of clonal expansion Chen Wang					
3:30 - 3:50 pm	Why do CLL patients die? David Dawe					
3:50 - 4:10 pm	Update on the Manitoba CLL clinic Rajat Kumar					
4:10 - 5:00 pm	Unique CLL cases Loree Larratt					
7:00 pm	Dinner					

The Current Restaurant Inn at the Forks

Friday, October 1, 2010

8:00 - 8:30 Breakfast

Session III — Basic Science Studies in CLL Chair: Michael Voralia

	Chair: Michael Voralia			
8:30 - 8:55	Telomeres and telomerase inhibition in CLL May Shawi			
8:55 - 9:20	Nuclear architecture of cancer cells Sabine Mai			
9:20 - 9:45	Inhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) Ganchimeg Ishdorj			
9:45 - 10:10	Genetic predispositions to chronic B cell malignancies Linda Pilarski			
10:10 - 10:35	Coffee			
10:35 - 11:00	Reversal of drug-resistance in CLL using dasatinib Raquel Aloyz			
11:00 - 11:25	Influencing stromal cell adhesion in CLL Sandrine Lafarge / Aaron Marshall			
11:25 - 11:50	Mechanisms of dasatinib resistance Raquel Aloyz			
11:50 - 12:00	Closing Remarks			
12:00 pm	Lunch			